- Home
- HE vs AUPH Comparison
HE vs AUPH Comparison
Compare HE & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HE | AUPH |
|---|---|---|
| Founded | 1891 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | HE | AUPH |
|---|---|---|
| Price | $10.44 | $16.17 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $13.25 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 2.0M | 921.0K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 106.32 | ★ 5075.00 |
| EPS | ★ 0.89 | 0.53 |
| Revenue | ★ $3,086,896,000.00 | $283,055,000.00 |
| Revenue This Year | $7.00 | $17.54 |
| Revenue Next Year | $4.06 | $15.74 |
| P/E Ratio | ★ $11.61 | $30.66 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $10.28 | $10.34 |
| 52 Week High | $17.33 | $19.25 |
Technical Indicators
Market Signals| Indicator | HE | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 25.36 | 50.24 |
| Support Level | N/A | $15.55 |
| Resistance Level | $13.82 | $16.40 |
| Average True Range (ATR) | 0.27 | 0.38 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 15.24 | 13.95 |
Price Performance
Historical ComparisonAbout HE Hawaiian Electric Industries Inc.
Hawaiian Electric Industries is the parent company of three Hawaii-based regulated utilities and owns a 10% minority interest in Hawaii's American Savings Bank. The utilities provide electricity on the islands of Oahu, Hawaii, Maui, Molokai, and Lanai.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.